Eli Lilly & Co (LLY) - Revenue Change due to Price (I:ELCL1EJ9)
Level Chart
Basic Info
|
Eli Lilly & Co (LLY) - Revenue Change due to Price is at -5.00%, compared to -10.00% last quarter and -4.00% last year. This is lower than the long term average of -1.76%. |
|
Revenue Change due to Price refers to the percentage change in Eli Lilly & Co's total revenue that is attributed to changes in the prices of its products and services. This metric helps investors, analysts, and stakeholders understand the impact of price changes on the company's overall revenue growth or decline. |
| Report | Fiscal.ai |
| Category | Segments & KPIs |
| Region | United States |
| Source | Fiscal.ai |
|
Data provided via Fiscal.ai |
Stats
| Last Value | -5.00% |
| Latest Period | Dec 2025 |
| Last Updated | Mar 23 2026, 14:09 EDT |
| Next Release | May 15 2026, 08:30 EDT (E) |
| Long Term Average | -1.76% |
| Average Growth Rate | 81.29% |
| Value from Last Quarter | -10.00% |
| Change from Last Quarter | N/A |
| Value from 1 Year Ago | -4.00% |
| Change from 1 Year Ago | N/A |
| Frequency | Quarterly |
| Unit | Percent |
| Adjustment | N/A |
| Download Source File |
Historical Data
| Date | Value |
|---|---|
| December 31, 2025 | -5.00% |
| September 30, 2025 | -10.00% |
| June 30, 2025 | -6.00% |
| March 31, 2025 | -6.00% |
| December 31, 2024 | -4.00% |
| September 30, 2024 | 6.00% |
| June 30, 2024 | 10.00% |
| March 31, 2024 | 10.00% |
| December 31, 2023 | 16.00% |
| September 30, 2023 | 6.00% |
| June 30, 2023 | 0.00% |
| March 31, 2023 | -5.00% |
| December 31, 2022 | -3.00% |
| Date | Value |
|---|---|
| September 30, 2022 | -7.00% |
| June 30, 2022 | -11.00% |
| March 31, 2022 | -3.00% |
| December 31, 2021 | -3.00% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | -2.00% |
| March 31, 2021 | -4.00% |
| December 31, 2020 | -4.00% |
| September 30, 2020 | -5.00% |
| June 30, 2020 | -7.00% |
| March 31, 2020 | -6.00% |
| December 31, 2019 | -1.00% |
News
Basic Info
|
Eli Lilly & Co (LLY) - Revenue Change due to Price is at -5.00%, compared to -10.00% last quarter and -4.00% last year. This is lower than the long term average of -1.76%. |
|
Revenue Change due to Price refers to the percentage change in Eli Lilly & Co's total revenue that is attributed to changes in the prices of its products and services. This metric helps investors, analysts, and stakeholders understand the impact of price changes on the company's overall revenue growth or decline. |
| Report | Fiscal.ai |
| Category | Segments & KPIs |
| Region | United States |
| Source | Fiscal.ai |
|
Data provided via Fiscal.ai |
Stats
| Last Value | -5.00% |
| Latest Period | Dec 2025 |
| Last Updated | Mar 23 2026, 14:09 EDT |
| Next Release | May 15 2026, 08:30 EDT (E) |
| Long Term Average | -1.76% |
| Average Growth Rate | 81.29% |
| Value from Last Quarter | -10.00% |
| Change from Last Quarter | N/A |
| Value from 1 Year Ago | -4.00% |
| Change from 1 Year Ago | N/A |
| Frequency | Quarterly |
| Unit | Percent |
| Adjustment | N/A |
| Download Source File |
Related Securities
Related Indicators
| Eli Lilly & Co (LLY) - Immunology Revenue | 1.541B USD |
| Eli Lilly & Co (LLY) - Neuroscience Revenue | 460.00M USD |